Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 4, 2019

View Archived Issues

Targeted protein degradation with DGY-08-097 shows promise for hepatitis C virus treatment

Discovery and preclinical characterization of c-KIT kinase inhibitor CHMFL-KIT-64

Vulnerable brains can be steered towards healthy development

Four-way interaction screen gives clues to drug effects

FDA clears IND application for phase I/II study of OBI-999

Inhibrx announces phase I dose-escalation data for INBRX-109

Kura Oncology presents phase II results for tipifarnib in HRAS-mutant urothelial carcinoma

Positive phase II data presented for CTP-543 in patients with alopecia areata

TAS-4464 demonstrates potent antitumor activity in hematologic and solid tumor models

BMS-986235 shows efficacy in preclinical models of heart failure

Fulacimstat does not improve standard of care treatment in CHIARA MIA 2 study

Biogen explores non-covalent activation of NRF2 for neurodegenerative and other disorders

Machine learning from adversity speeds compound development

Discovery of a first-in-class dual adenosine A2A/A2B receptor antagonist

Phase III AMPLIFY study of phosphate absorption inhibitor tenapanor meets primary endpoint

Pfizer synthesizes new KRAS inhibitors

Positive preclinical data presented for Cocrystal Pharma's CC-42344

Turning Point Therapeutics reports new data on repotrectinib and TPX-0046

Medshine Discovery divulges kynurenine production inhibitors

Phase II trial of AR-105 for ventilator-associated pneumonia does not meet primary endpoint

Jiangsu Aosaikang Pharmaceutical identifies H+/K+ ATPase inhibitors

Beijing Scitech-Mq Pharmaceuticals describes RET and VEGFR2 inhibitors

InnoCare Pharma identifies TRK inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...